Published in Hepatitis Weekly, June 14th, 2004
SciClone has earned a $1,000,000 milestone payment from Sigma-Tau for successfully meeting the enrollment objective. SciClone expects all patients to have completed therapy and the observation period by the end of 2005. Data from both trials are expected to be available in early 2006.
Eduardo Martins, vice president of Medical Affairs of SciClone, commented, "We are pleased to reach this milestone in our efforts to develop the combination of Zadaxin and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.